Random Biopsies Taken During Colonoscopic Surveillance of Patients With Longstanding Ulcerative Colitis: Low Yield and Absence of Clinical Consequences
- 1 May 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 109 (5), 715-722
- https://doi.org/10.1038/ajg.2011.93
Abstract
To evaluate the yield and clinical impact of random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis (UC). Retrospective analysis of 1,010 colonoscopies performed from 1998 to 2008. Colonoscopy and pathology reports were reviewed to assess the yield and clinical impact of random biopsies. In total, 475 patients with UC who underwent colonoscopy at the Academic Medical Centre Amsterdam were included in this study. The main outcome measures are neoplasia yield per-colonoscopy and clinical impact per-patient of random biopsies. Of all colonoscopies, 466 were performed for surveillance (in 167 patients) during which 11,772 random biopsies were taken (median 29). Overall, neoplasia was detected in 88 colonoscopies (53 patients): in 75 colonoscopies (85%) by targeted biopsies only and in 8 (9.1%) by both targeted and random biopsies. Neoplasia was detected in random biopsies only in five (5.7%) colonoscopies in four (7.5%) patients. Two of these four patients with neoplasia detected only by random biopsies had visible neoplasia in previous colonoscopies. One patient had unifocal low-grade intraepithelial neoplasia (LGIN) that could not be confirmed in three subsequent colonoscopies. The last patient had multifocal LGIN and suspicious appearing ulcerations. Proctocolectomy confirmed the presence of neoplasia. The yield of random biopsies is low whereas UC-associated neoplasia is macroscopically visible in 94% of colonoscopies. During 10-year surveillance, neoplasia was detected in only random biopsies in four patients of whom only one had clinical consequences. The low yield and lack of clinical consequences from random biopsies in this high-risk population raise questions about the necessity and cost-effectiveness of their routine use during UC surveillance.Keywords
This publication has 17 references indexed in Scilit:
- Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?Scandinavian Journal of Gastroenterology, 2008
- Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?Gastrointestinal Endoscopy, 2007
- Chromoscopy-Guided Endomicroscopy Increases the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative ColitisGastroenterology, 2007
- Indigo Carmine-Assisted High-Magnification Chromoscopic Colonoscopy for the Detection and Characterisation of Intraepithelial Neoplasia in Ulcerative Colitis: A Prospective EvaluationEndoscopy, 2005
- Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2005
- Most dysplasia in ulcerative colitis is visible at colonoscopyGastrointestinal Endoscopy, 2004
- Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitisGut, 2004
- Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitisGastroenterology, 2003
- Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel diseaseGut, 2002
- DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitisGastroenterology, 1992